SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 2, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on May 1, 2025, as part of an ongoing buyback program.
Key Financial Metrics and Transaction Details
- Transaction Date: May 1, 2025
- Shares Purchased: 709,955 ordinary shares
- Price Range: 1,450.50p (Low) to 1,478.50p (High)
- Volume-Weighted Average Price (VWAP): 1,461.88p
- Trading Venue: London Stock Exchange (XLON)
- Broker: Citigroup Global Markets Limited
- Treasury Shares Held: 205,510,063 (post-transaction)
- Shares in Issue (excluding Treasury): 4,109,731,315
- Total Voting Rights: 4,109,731,315
Material Changes and Program Status
The purchase was executed pursuant to a non-discretionary agreement entered into on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, GSK has purchased an aggregate of 36,439,760 ordinary shares. The shares acquired in this transaction are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section of GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program initiated on February 24, 2025.
- Confirm the impact of the 205,510,063 Treasury shares on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2024 Form 20-F for context on the forward-looking statements mentioned.
- Check subsequent filings for updates on the total volume of shares repurchased under the current program.